PMID: 7536458Mar 1, 1995Paper

Comparative genomic hybridization in the investigation of myeloid leukemias

Genes, Chromosomes & Cancer
M BentzP Lichter

Abstract

Comparative genomic hybridization (CGH) was used for the examination of ten cases of myeloid leukemia (eight acute myeloid leukemias and two myelodysplastic syndromes). In five cases, genomic gains or losses were identified, which mapped to chromosomal regions known to be involved in this group of malignancies. In comparison to the results obtained by banding analysis, discrepancies were found in three of the ten cases; in two cases, chromosomal imbalances were not identified by CGH because they were present only in small subclones. In the other case, there were no evaluable metaphase cells for banding analysis; CGH revealed an overrepresentation of chromosome 8, which was confirmed by interphase cytogenetics with a chromosome 8-specific alphoid probe. All abnormalities revealed by CGH were confirmed by G-banding or subsequent interphase cytogenetic analysis, which demonstrates the high specificity of the method. Furthermore, in all cases, CGH identified the chromosomal imbalances present in the major clone as detected by banding analysis. The good correlation between CGH and chromosome banding results in myeloid leukemias makes this tumor a good model for the assessment of tools that are developed for automated and quantitativ...Continue Reading

References

Oct 1, 1990·Cancer Genetics and Cytogenetics·L M Secker-Walker
Aug 4, 1973·Lancet·O SanchezJ J Yunis
Oct 15, 1983·International Journal of Cancer. Journal International Du Cancer·Y S Li
Jun 1, 1982·British Journal of Haematology·J M BennettC Sultan
Jan 1, 1995·Cytometry·S du ManoirT Cremer
Jan 1, 1995·Cytometry·C LundsteenT Gerdes
Mar 15, 1994·Proceedings of the National Academy of Sciences of the United States of America·A KallioniemiF M Waldman

❮ Previous
Next ❯

Citations

Jan 1, 1995·Cytometry·C LundsteenT Gerdes
Jul 1, 1996·Leukemia Research·J Anastasi
Jun 20, 2002·Cancer Genetics and Cytogenetics·Stéphanie StruskiPascale Cornillet-Lefebvre
Jan 15, 1998·Cancer Genetics and Cytogenetics·E P NachevaA R Green
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·S Solinas-ToldoP Lichter
Feb 22, 2001·The Journal of Experimental Medicine·D A Largaespada
Apr 5, 2000·Molecular Pathology : MP·M M WeissP J van Diest
Apr 12, 2002·International Journal of Cancer. Journal International Du Cancer·Ralf J RiekerGunhild Mechtersheimer
May 14, 2005·Cancer Letters·Ralf J RiekerGunhild Mechtersheimer
Aug 25, 2004·Cancer Genetics and Cytogenetics·Sílvia CasasJorge Sierra
Nov 15, 2007·Cytogenetic and Genome Research·J SuelaJ C Cigudosa
Jul 9, 1999·The Journal of Pathology·L A James
Jan 8, 2000·Journal of Inorganic Biochemistry·L R HiornsB Leyland-Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.